The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
J Affect Disord. 2024 Dec 1;366:44-58. doi: 10.1016/j.jad.2024.08.150. Epub 2024 Aug 24.
This study aimed to explore the relationship between flavonoids intake and the prevalence and all-cause mortality of depressive symptoms in American adults.
Analyzing 2007-2008, 2009-2010, and 2017-2018 NHANES data, we examined the association between dietary flavonoid and depressive symptoms, including specific subclasses assessment and mortality outcomes tracking until December 31, 2019. Our methodology included weighted multivariate logistic regression, weighted cox proportional hazards regression and restricted cubic spline (RCS) models, supported by stratified and sensitivity analyses.
Among the 12,340 participants in total, 1129 exhibited depressive symptoms. The multiple logistic regression analysis showed a significant reduction in total flavonoid and subclass intake in individuals with current depressive symptoms. Adjusted odds ratios (ORs) for the highest quartiles were 0.69 for anthocyanidins and 0.63 for flavones. Interaction effects emerged in non-hypertensive, higher-income, and normal-weight groups for flavones intake. The RCS model indicated an L-shaped association between depressive symptoms and total flavonoid intake, with inflection points at 346 mg/day. During a median follow-up of 119 months, 148 deaths occurred among patients with depressive symptoms. Hazard ratios (HRs) for all-cause mortality showed a significant positive correlation between total flavonoid intake and survival in model 1 (HR = 0.56), with an optimal intake range of 45.2-948.3 mg/day according to the RCS model.
The study relied on U.S. population survey data, potentially limiting generalizability. Unmeasured confounding factors may exist, and genetic factors were not considered.
Adequate intake of flavonoids, especially anthocyanidins and flavones, is associated with reduced odds of depressive symptoms. Additionally, optimal intake ranges of flavonoid intake for mental health benefits were observed for all-cause mortality in population with depressive symptoms.
本研究旨在探讨黄酮类化合物的摄入量与美国成年人抑郁症状的患病率和全因死亡率之间的关系。
我们分析了 2007-2008 年、2009-2010 年和 2017-2018 年 NHANES 数据,研究了饮食黄酮类化合物与抑郁症状之间的关系,包括特定亚类的评估和死亡率结果的跟踪,直至 2019 年 12 月 31 日。我们的方法包括加权多变量逻辑回归、加权 cox 比例风险回归和限制立方样条(RCS)模型,并辅以分层和敏感性分析。
在总共 12340 名参与者中,有 1129 人患有抑郁症状。多变量逻辑回归分析显示,当前患有抑郁症状的个体黄酮类化合物和亚类的摄入量显著减少。最高四分位数的调整比值比(OR)分别为花青素的 0.69 和类黄酮的 0.63。在非高血压、高收入和正常体重组中,类黄酮的摄入量出现了交互作用。RCS 模型显示,抑郁症状与总黄酮类化合物摄入之间呈 L 形关联,拐点为 346mg/天。在中位随访 119 个月期间,148 名患有抑郁症状的患者死亡。全因死亡率的风险比(HR)显示,在模型 1 中,总黄酮类化合物的摄入量与生存之间存在显著的正相关关系(HR=0.56),根据 RCS 模型,最佳摄入量范围为 45.2-948.3mg/天。
本研究依赖于美国人群调查数据,可能限制了其普遍性。可能存在未测量的混杂因素,且未考虑遗传因素。
摄入足够的黄酮类化合物,特别是花青素和类黄酮,与降低抑郁症状的几率有关。此外,在患有抑郁症状的人群中,观察到黄酮类化合物摄入的最佳范围与全因死亡率的精神健康益处有关。